CN106138194A - A kind of compound Chinese medicinal preparation treating hyperuricemia and preparation method thereof - Google Patents
A kind of compound Chinese medicinal preparation treating hyperuricemia and preparation method thereof Download PDFInfo
- Publication number
- CN106138194A CN106138194A CN201610562805.4A CN201610562805A CN106138194A CN 106138194 A CN106138194 A CN 106138194A CN 201610562805 A CN201610562805 A CN 201610562805A CN 106138194 A CN106138194 A CN 106138194A
- Authority
- CN
- China
- Prior art keywords
- preparation
- flos sophorae
- semen juglandis
- medicine
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 14
- 241000628997 Flos Species 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 43
- 210000000582 semen Anatomy 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- 238000001291 vacuum drying Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002481 ethanol extraction Methods 0.000 claims description 7
- -1 polyethylene pyrrole Pyrrolidone Polymers 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 208000000913 Kidney Calculi Diseases 0.000 claims description 3
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 231100001231 less toxic Toxicity 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 30
- 229940116269 uric acid Drugs 0.000 description 30
- 241000700159 Rattus Species 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 238000009835 boiling Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 2
- 206010038419 Renal colic Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- FXLJDRXREUZRIC-BAOOBMCLSA-N (3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO FXLJDRXREUZRIC-BAOOBMCLSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CPWPJLJWUXOOAB-UHFFFAOYSA-N benzene;bromine Chemical compound [Br].C1=CC=CC=C1 CPWPJLJWUXOOAB-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229950002752 oxipurinol Drugs 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of compound Chinese medicinal preparation treating hyperuricemia and preparation method thereof.It is characterized in that it is prepared from by the raw material of Chinese medicine medicine of following weight proportioning: Flos Sophorae 5～10, Semen Juglandis 2～6, the compound Chinese medicinal preparation of the present invention has determined curative effect, taking convenience, treating both the principal and secondary aspects of a disease, integrally-regulated, less toxic side effect and other advantages.
Description
Technical field
The invention belongs to food, health product, medicine and medical field, be specifically related to a kind of Chinese medicine treating hyperuricemia
Compound recipe, and the preparation method of its extract and preparation.
Technical background
Hyperuricemia is a kind of common metabolic disease, and sickness rate, in ascendant trend year by year, actively develops antihyperuricemic
The preventing and treating of disease and complication thereof has become the focus of current medical circle research.Chinese medicine prevention gout has long history, warp
Cross the clinical practice of thousands of years, have accumulated abundant medical experience, and define theoretical system and the Therapeutic Method of system.We
Come from Compendium of Material Medica (drawing " hospital's summary "), the micro-stir-fry of Flos Sophorae, Semen Juglandis two liang in side, wine without lime one clock.Decoct over thousands of boiling, heat
Clothes.Control furuncle swelling toxin ... but pain person all controls.According to modern study document analysis ancient prescription Chinese traditional medicine thing composition, main in discovery side
Composition is based on flavone compound, and modern study proves, flavone compound can pass through number of mechanisms, multiple target spot is prevented
Control metabolic arthritis and gout.
The modern medicine understanding to hyperuricemia: a source part for uric acid is to be decomposed generation by the purine in food through enzyme
Thanking (exogenous), another part is decomposed (interior by the catabolic nucleic acid of cells in vivo and other purine compounds
Source property).The excretion pathway of uric acid is mainly drained by kidney.Normal person produces uric acid about about 750mg average every day, its
In 1/3 with urine discharge, 1/3 is drained by intestinal or is bacterially decomposed in intestinal.When imbalance occurs in above uric acid metabolism
Abnormality, can cause hyperuricemia.
The understanding of the complication such as the gout that metabolic arthritis is caused by the traditional Chinese medical science: the cause of disease mostly is surfeit greasy and surfeit flavour, dysfunction of the spleen in transportation or
Innate deficiency, kidney the clear failing to ascend and the turbid failing to descend, so that life in damp and hot turbid poison, the heresy that affection of exogenous wind-cold of holding concurrently again is wet, attacks meridians, QI-blood circulation
The most smooth.Pathogenesis is that the turbid numbness of wet hot phlegm hinders meridians, stagnation of QI and blood may bring about pain.Along with the raising of modern life level, people suffer from metabolic arthritis and cause
Mostly the reason of goat is due to polyphagia delicious food, is negligent of work, broadly falls into greatly the beriberoid pyretic arthralgia in traditional Chinese medical science arthromyodynia.Medication: main
Concentrate in the utilization of tonic, drug for invigorating blood circulation and eliminating stasis, antipyretic, damp-clearing drug and five aspects of drugs for dispelling internal cold.
What the most clinical conventional uricosuric was commonly used at present has following three kinds: (1) benemid (probenicid the third sulphur
Relax): main suppression renal tubules causes acidum ethacrynicum effect to the re-absorption of uric acid.Draw for preventing uric acid from having when kidney is discharged in a large number
Playing kidney damage and the side effect of renal calculus, there is erythra, heating, the intestines and stomach stimulation, renal colic and evokes acute in about 5% patient
The side effect such as work.(2) sulphinpyrazone (sulfinpyrazone): be the derivant of phenylbutazone, suppression renal tubules is to uric acid again
Absorbing, uricotelism relatively probenecid is strong, and this medicine has stimulation to gastric mucosa, and Peptic Ulcers patient be cautious use of.(3) benzbromarone
(benzbromarone): for strong acidum ethacrynicum medicine, extensively applying in Europe and have for many years, toxic action is slight, does not affects
, seldom there is erythra, heating, but can have intestines and stomach reaction, renal colic and excite acute arthritis to show effect in hepatic and renal function.
Suppression uric acid synthetic drug is to only having different purine alcohol (allopurinol) so far, and this medicine can suppress xanthine
Oxidase, makes hypoxanthine and xanthine can not be converted into uric acid, itself then gradually aoxidizes in human body, generate soluble in water
Different xanthine (oxipurinol) through urine ejection, and corresponding nucleotide can be transformed in the presence of PRPP, consume PRPP, also
PRPPAT can be suppressed, make IMP synthesis reduce, thus serum Uric Acid Concentration can be reduced rapidly, suppression tophus and kidney urate calculus
Synthesis, and promote tophus to dissolve.Individuals patients can have heating, allergic rash, suffer from abdominal pain, suffer from diarrhoea, leukocyte and platelet subtract
Few, the even side effect such as liver function injury, drug withdrawal and give corresponding treatment and generally individually can recover, occasionally necrosing property dermatitis is then
It is in a bad way, should i.e. rescue.
To sum up, the most clinical conventional uric acid resisting medicine all has certain side effect, and in we, medical material used is middle traditional Chinese medicines
Allusion quotation records kind, and is the national medicine-food two-purpose kind eating Bureau of Drugs Supervision's announcement, and in new drug research, safety can exempt to do, it is contemplated that
Its safety and effectiveness is the sharpest edges of clinical application.
The purpose of the present invention is contemplated to the uric acid resisting Chinese medicine providing a kind for the treatment of both the principal and secondary aspects of a disease, integrally-regulated and toxic and side effects is low
Compound recipe and preparation thereof.
Summary of the invention
The present invention provides a kind of compound Chinese medicinal preparation treating hyperuricemia, and described preparation is by following weight proportioning
Medicine crude drug is prepared from: Flos Sophorae 5～10, Semen Juglandis 2～6.Preferably, described preparation is by the raw material of Chinese medicine of following weight proportioning
Medicine is prepared from: Flos Sophorae 10, Semen Juglandis 1～5.It is furthermore preferred that described preparation is prepared by the raw material of Chinese medicine medicine of following weight proportioning
Form: Flos Sophorae 10, Semen Juglandis 2～4.Most preferred described preparation is prepared from by the raw material of Chinese medicine medicine of following weight proportioning: Chinese scholartree
Spend 10, Semen Juglandis 2.
Compound preparation of the present invention, for the acceptable any dosage form of medicine, food or health product.Described dosage form is selected
From: liquid preparation, tablet, capsule, granule, drop pill, pill, powder, unguentum.Described dosage form contains adjuvant if desired,
Described adjuvant is selected from: microcrystalline Cellulose, starch, dextrin, sucrose, stachyose, carboxymethyl starch sodium, low substituted hydroxy-propyl fiber
Element, Polyethylene Glycol, polyvinylpyrrolidone, Pulvis Talci, magnesium stearate, sorbitan mono-oleic acid ester, glycine, gelatin, glycerol,
Water, ethylparaben.
The present invention further provides the preparation method of the compound Chinese medicinal preparation of the present invention, described method is selected from
(1) water extraction method: take Flos Sophorae, Semen Juglandis, adds 5～15 times amount water, decocts 2～3 times, each 0.5～2 hour, closes
And decocting liquid, filter, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize, obtain dry extract
Powder；
(2) alcohol extraction is followed the example of: take Flos Sophorae, Semen Juglandis, adds 5～15 times amount 30～90% ethanol extraction 2～3 times, each 0.5～
2 hours, united extraction liquid, filter, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, powder
Broken, obtain dry extract.
The present invention farther includes described compound Chinese medicinal preparation in preparation treatment hyperuricemia or diseases related: bitterly
Application in wind arthritis, gouty nephropathy, gouty renal calculus, gouty heart disease, gouty hypertension drug.
In the present invention, Flos Sophorae, preferably Flos Sophorae (parched), there is clearing away heat-damp and promoting diuresis, effect of cooling blood for hemostasis, the heat that can purify the blood point.Core
Semen Persicae, warm in nature and the driest, can benefiting qi and nourishing blood, the strong body of benefit essence, qualcomm meridian, moisten blood vessels.Two medicines phases 5, can search the rheumatic fever of meridians
Poison, thus treat furuncle swelling toxin, but pain person all controls.
Below by way of experimental data, beneficial effects of the present invention is described
It is prepared as follows Flos Sophorae, Semen Juglandis dry extract；And carry out pharmacological experiment study, its pharmacological experiment study result
As follows:
1. the preparation of test medication:
Take Flos Sophorae 500g, add 9 times amount 30% ethanol and decoct 2 times, extract 2 hours after boiling, collecting decoction every time, filter, subtract
Pressure is concentrated into the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverizes, and crosses 20 mesh sieves, obtains Flos Sophorae dry extract
Powder.
Take Flos Sophorae Semen Juglandis 500g, add 9 times amount 30% ethanol and decoct 2 times, extract 2 hours after boiling, collecting decoction, filter every time
Cross, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize, cross 20 mesh sieves, obtain Semen Juglandis
Dry extract.
Take Flos Sophorae 500g, Semen Juglandis 50g, add 9 times amount 30% ethanol and decoct 2 times, extract 2 hours after boiling every time, merge and decoct
Liquid, filters, is evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), and vacuum drying is pulverized, and crosses 20 mesh sieves,
Flos Sophorae+Semen Juglandis (10:1) dry extract.
Take Flos Sophorae 500g, Semen Juglandis 100g, add 9 times amount 30% ethanol and decoct 2 times, extract 2 hours after boiling every time, merge and decoct
Liquid, filters, is evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), and vacuum drying is pulverized, and crosses 20 mesh sieves,
Flos Sophorae+Semen Juglandis (10:2) dry extract.
Take Flos Sophorae 500g, Semen Juglandis 200g, add 9 times amount 30% ethanol and decoct 2 times, extract 2 hours after boiling every time, merge and decoct
Liquid, filters, is evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), and vacuum drying is pulverized, and crosses 20 mesh sieves,
Flos Sophorae+Semen Juglandis (10:4) dry extract.
2. pharmacological experiment study:
2.1 packets and administration:
Research selects male SD rat 80 only to test.It is divided into normal group, model group by body weight stratified random.Normal group
(10) give full diet, drinking-water；Model group (70) give full diet and 10% fructose water.After modeling success, model
Group rat is randomly divided into benzbromarone comparison medicine group, Flos Sophorae extract group, Semen Juglandis extract group, Flos Sophorae+Semen Juglandis (10:1)
Extract group, Flos Sophorae+Semen Juglandis (10:2) extract group, Flos Sophorae+Semen Juglandis (10:4) extract group, often group 10.The administration phase
Between each process group continue to give 10% modeling feedstuff.
Normal group, model group give 0.5%CMC-Na aqueous solution gavage, and remaining group is dissolved in 0.5%CMC-by relative medicine
Na (ultrasonic dissolution) gastric infusion, observes the impact on rat uric acid level of the different parts extract respectively, is administered volume 1ml/
100g body weight, every day gavage once, be administered 21 days.Within every 7 days, weigh the weight of animals, biochemical process detection serum uric acid level.
Table 1 experiment packet and number of animals
Medication:
Route of administration: gastric infusion (intends route of administration with people's clinic consistent).
Administration volume: 1ml/100g body weight.
Administration time: therapeutic after hyperuricemia occurs in rat, presses body weight gavage 1 time morning every day.
The administration time limit: successive administration 14 days.
Test sample is prepared: matching while using, weighs a certain amount of herbal mixture component, the CMC-of the 0.5% of addition respective volume
Na solution, ultrasonic, standby after stirring and evenly mixing.
Giving of test sample: extract medicinal liquid with disposable syringe, by document " rat hyperuricemia syndrome manifestations feature and
The intervention study of Herba Cichorii " operate.
2.2 Testing index
Within every 7 days, animal is weighed once.Within every 7 days, blood is taken once, centrifugation serum during modeling and during being administered.Biochemical
Detection serum uric acid (UA) level.
2.3 result statistics and analysis
Result represents with means standard deviationBody weight and Biochemical Indices In Serum add up soft with SPSS 17.0 respectively
Part calculates the meansigma methods and standard deviation often organized and carries out ANOVA variance analysis.
Serum uric acid (UA) level changes: compared with normal group, the 7th, 14,21,28 days model group rats serum UA of modeling
Level significantly raises (P < 0.05).
With model group ratio, it is administered the 7th day benzbromarone group rat blood serum UA level in reducing trend, is administered the 14th day benzene bromine
Grand group of rat blood serum UA of horse significantly reduces (P < 0.05)；It is administered the 7th day Flos Sophorae extract group, Semen Juglandis extract and compatibility 1 to carry
Taking thing group rat blood serum UA level is reduction trend, but has no significant difference (P ＞ 0.05)；It is administered 14 days Flos Sophorae extract groups
And compatibility 1 extract group rat blood serum UA level significantly reduces (P < 0.05)；It is administered the 7th day, 14 days compatibility 2 extract groups and compatibility
3 extract group rat blood serum UA levels significantly reduce (P < 0.05).Concrete outcome is shown in Table 2, table 3:
Rat blood serum UA level during table 2, modeling (μmol/L)
Note: # and normal group are than P < 0.05
Table 3, be administered during rat blood serum UA level (μm ol/L, n=12)
Note: # and normal group are than P < 0.05；
* with model group than P < 0.05, * * with model group than P < 0.01
Conclusion: under this experiment condition, the 7th day-21 days model group rats serum uric acid levels of modeling are significantly higher than normally
Group rat, hyperuricemia model is moulded successfully.It is administered 7,14 days compatibilities 2 and compatibility 3 extract group all has lasting uric acid resisting to make
With.Single medicinal material Flos Sophorae is being administered the 14th talent's notable uric acid resisting effect of display, and single medicinal material Semen Juglandis uric acid resisting effect is inconspicuous.
Show that Flos Sophorae, Semen Juglandis extract can significantly improve drug effect after carrying out compatibility, played significant synergism.
Detailed description of the invention
[embodiment 1] alcohol extraction procedure
1, individually extract:
Take Flos Sophorae 100g, add 9 times amount 30% ethanol heating extraction 2 times, extract 2 hours after boiling, united extraction liquid, filter every time
Cross, reclaim ethanol, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize, obtain sophoranl
Promoting extract powder 37g, paste-forming rate is 35-40%.
Taking Semen Juglandis 100g, smash to pieces, add 9 times amount 30% ethanol heating extraction 2 times, extract 2 hours every time after boiling, merging carries
Take liquid, filter, reclaim ethanol, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize,
Obtaining Semen Juglandis alcohol extraction dry extract 12g, paste-forming rate is 10-15%.
2, mixed extraction:
Taking Flos Sophorae 100g, Semen Juglandis 20g, add 9 times amount 30% ethanol extraction 2 times, extract 2 hours every time after boiling, merging carries
Take liquid, filter, reclaim ethanol, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize,
Obtaining sophoranl and promote extract powder 41g, paste-forming rate is 33-38%.
[embodiment 2] water extracting method
1, individually extract:
Take Flos Sophorae 100g, add 9 times amount soak by water 2 times, each 2 hours, collecting decoction, filter, be evaporated to the closeest
Degree is the thick paste of 1.30～1.35 (60 DEG C), vacuum drying, pulverizes, and obtains Flos Sophorae water and promotes extract powder 42g, and paste-forming rate is 35-
40%.
Take Semen Juglandis 100g, smash to pieces, add 9 times amount soak by water 2 times, each 2 hours, collecting decoction, filter, be evaporated to
Relative density is the thick paste of 1.30～1.35 (60 DEG C), vacuum drying, pulverizes, and obtains Semen Juglandis water and promotes extract powder 8g, paste-forming rate
For 7-12%.
2, mixed extraction:
Take Flos Sophorae 100g, Semen Juglandis 20g, add 9 times amount soak by water 2 times, each 2 hours, collecting decoction, filter, reduce pressure dense
It is reduced to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize, obtain Flos Sophorae water and promote extract powder 45g, go out cream
Rate is 35-40%.
The preparation of [embodiment 3] liquid preparation
Take Flos Sophorae 25, Semen Juglandis 5, with 9 times amount 30% ethanol extraction 2 times, extract 2 hours, united extraction liquid every time,
It is evaporated to 100 liters, adds Mel 2, mixing, filter, obtain oral liquid.
Prepared by [embodiment 4] solid beverage
Take Flos Sophorae 25, Semen Juglandis 10, with 9 times amount 30% ethanol extraction 2 times, extract 2 hours, united extraction every time
Liquid, filters, and with milk powder 8, sucrose 2 mixes, and is evaporated to density 1.10 (60 DEG C) left and right, is spray-dried, fills aluminium plastic bag,
Every bag of 3g, obtains solid beverage.
Prepared by [embodiment 5] granule
Take Flos Sophorae water extract 15g, Semen Juglandis water extract 5g mixing, add dextrin 15g, Herba Stachydis Japonicae Icing Sugar 10g, mixing, use
90% appropriate amount of ethanol makes granule, is dried, granulate, obtains granule.
The preparation of [embodiment 6] tablet
Take Flos Sophorae 25, Semen Juglandis 15, with 9 times amount 30% ethanol extraction 2 times, extract 2 hours, united extraction every time
Liquid, filters, and concentrates, and adds starch, dextrin, Icing Sugar, prepares granule, and tabletting i.e. obtains tablet.
The preparation of [embodiment 7] capsule
Take Flos Sophorae 25, Semen Juglandis 2.5, with 9 times amount 30% ethanol extraction 2 times, extract 2 hours, united extraction every time
Liquid, filters, and concentrates, and adds starch, dextrin, Icing Sugar, prepares granule, encapsulated i.e. obtains capsule.
Claims (9)
1. the compound Chinese medicinal preparation treating hyperuricemia, it is characterised in that described preparation is by following weight proportioning
Medicine crude drug is prepared from: Flos Sophorae 5～10, Semen Juglandis 2～6.
2. compound preparation as claimed in claim 1, it is characterised in that described preparation is by the raw material of Chinese medicine medicine of following weight proportioning
It is prepared from: Flos Sophorae 10, Semen Juglandis 1～5.
3. compound preparation as claimed in claim 1, it is characterised in that described preparation is by the raw material of Chinese medicine medicine of following weight proportioning
It is prepared from: Flos Sophorae 10, Semen Juglandis 2～4.
4. compound preparation as claimed in claim 1, it is characterised in that described preparation is by the raw material of Chinese medicine medicine of following weight proportioning
It is prepared from: Flos Sophorae 10, Semen Juglandis 2.
5. compound preparation as claimed in claim 1, for the acceptable any dosage form of medicine, food or health product.
6. compound preparation as claimed in claim 1, described dosage form is selected from: liquid preparation, tablet, capsule, granule, drop pill
Agent, pill, powder, unguentum.
7. compound preparation as claimed in claim 1, it is characterised in that containing adjuvant if desired, described adjuvant is selected from: crystallite is fine
Dimension element, starch, dextrin, sucrose, stachyose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, Polyethylene Glycol, polyethylene pyrrole
Pyrrolidone, Pulvis Talci, magnesium stearate, sorbitan mono-oleic acid ester, glycine, gelatin, glycerol, water, ethylparaben.
8. compound preparation preparation method as claimed in claim 1, it is characterised in that: described method is selected from
(1) water extraction method: take Flos Sophorae, Semen Juglandis, adds 5～15 times amount water, decocts 2～3 times, each 0.5～2 hour, merges and decoct
Liquid, filters, is evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), and vacuum drying is pulverized, obtained dry extract；
(2) alcohol extraction is followed the example of: take Flos Sophorae, Semen Juglandis, adds 5～15 times amount 30～90% ethanol extraction 2～3 times, and each 0.5～2 is little
Time, united extraction liquid, filter, be evaporated to the thick paste that relative density is 1.30～1.35 (60 DEG C), vacuum drying, pulverize,
Obtain dry extract.
9. the compound preparation described in claim 1 is in preparation treatment hyperuricemia or diseases related: gouty arthritis, bitterly
Application in wind nephropathy, gouty renal calculus, gouty heart disease, gouty hypertension drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562805.4A CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562805.4A CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106138194A true CN106138194A (en) | 2016-11-23 |
| CN106138194B CN106138194B (en) | 2018-04-03 |
Family
ID=58059266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610562805.4A Active CN106138194B (en) | 2016-07-16 | 2016-07-16 | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106138194B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107259006A (en) * | 2017-06-19 | 2017-10-20 | 黎金莲 | A kind of bamboo juice leaf of bamboo health protection tea for treating gout |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN102965252A (en) * | 2012-11-19 | 2013-03-13 | 青岛本草生物科技有限公司 | Healthcare wine for gout |
-
2016
- 2016-07-16 CN CN201610562805.4A patent/CN106138194B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101181345A (en) * | 2007-11-15 | 2008-05-21 | 南京大学 | Application of flos Sophora chromocor extract in the preparation of medicament for restrainting uric acid transporter URAT1 |
| CN102965252A (en) * | 2012-11-19 | 2013-03-13 | 青岛本草生物科技有限公司 | Healthcare wine for gout |
Non-Patent Citations (3)
| Title |
|---|
| 周大观: "《家庭常用治疗小窍门》", 30 November 2009 * |
| 曲波: "《食物就是最好的灵丹妙药》", 31 January 2014 * |
| 钱文文等: "槐花的营养保健功能及食品开发前景", 《农产品加工》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107259006A (en) * | 2017-06-19 | 2017-10-20 | 黎金莲 | A kind of bamboo juice leaf of bamboo health protection tea for treating gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106138194B (en) | 2018-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| WO2007006203A1 (en) | A capsule formulation for treating hypertension and coronary heart disease and process for preparation thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102895320A (en) | Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout | |
| CN103933224B (en) | A kind of Chinese medicine composition for treating gout | |
| CN104740451A (en) | Traditional Chinese medicine composition for treating hyperuricemia and application of traditional Chinese medicine composition | |
| CN104173458B (en) | A kind of have Chinese medicine composition preventing and treating hyperuricemia effect and preparation method thereof | |
| CN104069391B (en) | A kind of Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN108837121A (en) | A kind of Chinese medicine composition and preparation method thereof for treating high lithemia | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN106138194B (en) | A kind of compound Chinese medicinal preparation for treating hyperuricemia and preparation method thereof | |
| CN101317881A (en) | Traditional Chinese medicine compound and formulation for removing renal stone | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
| CN104337920A (en) | Traditional Chinese medicine composition for improving sleep quality | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN105267711A (en) | Pharmaceutical preparation for treating vertigo | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN113633712B (en) | Traditional Chinese medicine composition for treating gout and oral preparation based on traditional Chinese medicine composition | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN102068670B (en) | Chinese medicinal composition for treating hyperlipidemia | |
| CN106728718A (en) | A kind of Chinese medicine for treating hyperuricemia | |
| CN105901736A (en) | Application of composition containing green plum extract in preparation of uric acid decreasing healthcare products | |
| CN117919331A (en) | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure | |
| CN106266002A (en) | A kind of Chinese medicine composition treating hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |